Looking for support in planning and executing value and market access studies with RWE?

Leveraging Flatiron’s deep expertise in oncology evidence generation and HTA decision making, we are biopharma's trusted global RWE partner for:

• Characterizing natural history of disease

• Long-term survival extrapolation

• Indirect treatment comparison analyses

• Reassessment of marketed drugs

• High-impact research collaborations with biopharma companies and HTA bodies

Reach out for a custom approach—our data products and services can be flexibly configured